Physician profile
Brittany Combs
NPI 1528676178
$6,277.79
in general payments reported to CMS, 2019-2025
30 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.15 · 2023: $1,068 · 2024: $2,671 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,890 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,889.66 |
| Education | $352.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $973.57 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Janssen Biotech, INC. | $946.35 | 2023-2025 | Tremfya |
| Abbvie INC. | $770.42 | 2023-2025 | |
| Ucb, INC. | $711.81 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $625.50 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $483.22 | 2023-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $397.96 | 2023-2025 | Purified Cortrophin Gel |
| Sandoz INC. | $185.37 | 2024-2025 | Hyrimoz |
| Astrazeneca Pharmaceuticals LP | $153.26 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $113.83 | 2023-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $102.79 | 2024-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $98.12 | 2024-2025 | Strensiq |
| Scilex Pharmaceuticals INC. | $94.62 | 2022-2023 | Ztlido |
| Pfizer INC. | $85.20 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.95 | 2023-2025 | Cyltezo, Ofev, Spevigo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $71.82 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $56.95 | 2022-2023 | Xtampza, Belbuca |
| E.R. Squibb & Sons, L.L.C. | $53.40 | 2024-2025 | Orencia |
| Organon LLC | $51.46 | 2024-2025 | Hadlima, Renflexis |
| Amneal Pharmaceuticals LLC | $34.23 | 2023 | Lyvispah |
| Nevro Corp. | $30.02 | 2023 | Senza |
| Genentech USA, INC. | $29.56 | 2024-2025 | Actemra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.85 | 2023 | Relistor |
| Fresenius Kabi USA, LLC | $21.90 | 2023 | Idacio |
| Mindera Corp | $17.66 | 2025 | |
| Spinal Simplicity, LLC | $15.06 | 2023 | Ha Minuteman G3-R |
| Kiniksa Pharmaceuticals International, Plc | $15.01 | 2024 | Arcalyst |
| Biocon Biologics INC | $14.03 | 2023 | Hulio |
| Radius Health, INC. | $13.99 | 2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $8.88 | 2024 | Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.